Loading...
Back to narrative

543220: Nifty Inclusion Will Support Stronger Long-Term Upside Potential

Rising Disposable Incomes And Aging Populations Will Drive Healthcare Demand

543220 logo
543220
AnalystHighTarget
Not Invested
Published 16 Jun 2025

Update shared on 17 Dec 2025

Fair value Increased 3.33%
n/a
n/a
AnalystHighTarget's Fair Value
n/a
Loading
1Y
-7.8%
7D
-0.5%

Analysts have nudged their price target on Max Healthcare Institute up by ₹50 to ₹1,550 per share, citing stronger expected revenue growth, slightly higher profit margins, and a modestly lower future P/E multiple despite a marginal uptick in the assumed discount rate.

What's in the News

  • Board meeting scheduled on November 14, 2025, to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing)
  • Max Healthcare Institute added as a constituent to the benchmark Nifty 50 index, increasing its visibility and potential inclusion in passive investment portfolios (index announcement)

Valuation Changes

  • The fair value estimate has risen slightly from ₹1,500 to ₹1,550 per share, reflecting improved fundamentals.
  • The discount rate has inched up marginally from 12.73 percent to 12.76 percent, indicating a slightly higher perceived risk profile.
  • Revenue growth has increased meaningfully from about 36.7 percent to about 40.6 percent, implying stronger top line expectations.
  • Net profit margin has improved modestly from about 18.75 percent to about 18.94 percent, supporting a more profitable outlook.
  • The future P/E has fallen moderately from about 58.0x to about 53.3x, suggesting a less aggressive valuation multiple applied to higher earnings.

Have other thoughts on Max Healthcare Institute?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.